Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1993 Target Snapshot

DNA (cytosine-5)-methyltransferase 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
870Compounds
216Assays
3Approved Drugs
626.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

DNA (cytosine-5)-methyltransferase 1 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P26358. Start with acute myeloid leukemia, then reuse UniProt P26358 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with acute myeloid leukemia, then reuse UniProt P26358 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 2 linked drugs
Open source guide
Disease program
acute myeloid leukemia

DNA (cytosine-5)-methyltransferase 1 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.

Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include AZACITIDINE, DECITABINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 2 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats DNA (cytosine-5)-methyltransferase 1 as ChEMBL target CHEMBL1993, mapped to UniProt P26358. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
DNA (cytosine-5)-methyltransferase 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1993
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P26358
DNA (cytosine-5)-methyltransferase 1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether DNA (cytosine-5)-methyltransferase 1 is the right protein anchor across sources, using UniProt P26358 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why acute myeloid leukemia is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameDNA (cytosine-5)-methyltransferase 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP26358
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelDNA (cytosine-5)-methyltransferase 1
UniProt AccessionP26358
Component TypeProtein
Sequence Length1616 aa

DNA (cytosine-5)-methyltransferase 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as DNA (cytosine-5)-methyltransferase 1, mapped to UniProt P26358. Sequence length is 1616 aa.

Mapped IDP26358
Review nameDNA (cytosine-5)-methyltransferase 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

DNA (cytosine-5)-methyltransferase 1 shows approved-linked disease relevance led by acute myeloid leukemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
acute myeloid leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Approved-linked Approved
cancer
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Approved-linked Approved
chronic myelomonocytic leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Approved-linked Approved
myelodysplastic syndrome
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Approved-linked Approved
myeloid leukemia
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Approved-linked Approved
neoplasm
2 linked drugs · 2 direct · 2 efficacy
Linked drugAZACITIDINE
Linked drugDECITABINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with acute myeloid leukemia because it currently carries approved-linked support. Linked drugs include AZACITIDINE, DECITABINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseacute myeloid leukemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
1
Phase III
2
Phase II
Assay Mix

Activity Type Distribution

IC50571.0
KI3.0
EC5032.0
KD20.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3087498 9.52 IC50 0.3 Preclinical
CHEMBL2171169 8.54 IC50 2.9 Preclinical
CHEMBL83747 7.73 IC50 18.6 Preclinical
CHEMBL4215326 7.68 IC50 21.0 Preclinical
CHEMBL1201129 7.52 IC50 30.0 Approved
CHEMBL4208004 7.5 IC50 32.0 Preclinical
CHEMBL4212905 7.4 IC50 40.0 Preclinical
CHEMBL5613516 7.4 EC50 40.0 Preclinical
CHEMBL418052 7.15 IC50 71.0 Preclinical
CHEMBL4208010 7.14 IC50 73.0 Preclinical
Distribution

pChEMBL Value Distribution

185
5.0
71
5.5
71
6.0
45
6.5
7
7.0
7
7.5
0
8.0
1
8.5
0
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

DECITABINE
CHEMBL1201129
Approved 2006
Properties Compare Identifier
AZACITIDINE
CHEMBL1489
Approved 2004
Properties Compare Identifier
Assay Landscape

Assay Landscape

216
Total Assays
280
Tested Compounds
3
Assay Types
Binding — 212 assays, 280 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 139 200 5.9
cell-based format 65 68 5.1
assay format 8 12 5.8
Functional — 3 assays, 181 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 3 181 5.2
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine